Full text
| |
| Author(s): |
Vanessa Maciel Braulio da Fonseca
Total Authors: 1
|
| Document type: | Master's Dissertation |
| Press: | Ribeirão Preto. |
| Institution: | Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (PCARP/BC) |
| Defense date: | 2015-07-01 |
| Examining board members: |
Marcos de Carvalho Borges;
Flaviano dos Santos Martins;
Pérsio Roxo Júnior
|
| Advisor: | Marcos de Carvalho Borges |
| Abstract | |
The prevalence of asthma has increased in children and communities that adopt a Western lifestyle and become more urbanized. The hygiene hypothesis suggests that exposure to infections early in life can reduce the risk of asthma and other allergic diseases. Probiotics are live micro-organisms that confer a health benefit to the host. Treatment with Saccharomyces cerevisiae UFMG 905 protected mice against intestinal infections, prevented bacterial translocation and increased IL-10 production. There is no study of Saccharomyces cerevisiae in the prevention or treatment of asthma. The objective of this study was to evaluate the effects of viable Saccharomyces cerevisiae UFMG 905 administration in the prevention and treatment of asthma and the mechanisms involved. Male Balb/c mice were sensitized twice with ovalbumin (OVA) intraperitoneally, one week apart, and challenged with OVA intranasally for three days. Mice were treated by gavage with Saccharomyces cerevisiae UFMG 905 10 days before OVA sensitization and during challenges. Control mice received saline or PBS on the same days. After challenge, mice were ventilated with a small animal ventilator (FlexiVent®) and in vivo measurements of bronchial hyperresponsiveness were performed with increasing concentrations of methacoline aerosol (6.25, 12.5, 25 and 50 mg/ml). Bronchoalveolar lavage(BAL) was collected to quantify total and differential cell counts. Levels IL-4, IL-5, IL-10, IL-13 and IFN- in BAL and lung homogenate were measured by ELISA. Inflammatory cell number and collagen deposition were assed in lung tissues. Oral treatment with Saccharomyces cerevisiae UFMG 905 significantly decreased airway hyperresponsiveness, measured by total resistance (p<0,0001), central airway resistance(p<0,001) and tissue resistance (p<0,05). Saccharomyces cerevisiae UFMG 905 significantly attenuated total cell number (p<0,05) and the influx of eosinophil (p<0,001) to the airway lumen. Furthermore, inflammatory cell number in lung peripheral (p<0,001 and levels of IL-4 (p<0,05) in BAL and IL-5 (p<0,05) and IL-13 (p<0,05) in lung homogenate were significantly diminished by Saccharomyces cerevisiae UFMG 905.Of note, Saccharomyces cerevisiae UFMG 905 restored IL-10 (p<0,05) levels in lung tissue. In conclusion, oral administration of Saccharomyces cerevisiae 905 UFMG attenuated major asthma-like characteristics in a mouse model. These results showed that Saccharomyces cerevisiae UFMG 905 might have potential for prevention of asthma. (AU) | |
| FAPESP's process: | 13/02209-4 - Study of asthma prevention with the administration of viable Saccharomyces cerevisiae in a murine model of allergic asthma |
| Grantee: | Vanessa Maciel Braulio da Fonseca |
| Support Opportunities: | Scholarships in Brazil - Master |